持续葡萄糖监测对青少年和年轻成人1型糖尿病血糖控制的影响:一项随机临床试验
这项在美国14家内分泌诊所开展的随机临床试验纳入153例14–24岁、筛查HbA1c 7.5%–10.9%的1型糖尿病患者,1:1随机分为持续葡萄糖监测(CGM)组(n=74)和传统血糖仪监测(BGM)组(n=79)。主要终点为基线至26周HbA1c变化。CGM组基线HbA1c 8.9%、26周8.5%,BGM组基线及26周均为8.9%,校正组间差值-0.37%(95%CI -0.66%至-0.08%,P=0.01)。20项预设次要终点中,7项二分类HbA1c终点有3项、9项CGM指标有8项、4项患者报告结局有1项达到统计学显著差异。作者结论认为CGM较标准血糖监测小幅但统计学显著改善血糖控制,需进一步研究理解其临床重要性。
要点
- 在14–24岁1型糖尿病且筛查HbA1c 7.5%–10.9%的患者中,CGM组26周HbA1c 8.5% vs BGM组8.9%,校正组间差值-0.37%(95%CI -0.66%至-0.08%,P=0.01)。
- CGM组68%的参与者在第6个月每周使用CGM至少5天。
- 20项预设次要终点中,7项二分类HbA1c终点有3项、9项CGM指标有8项、4项患者报告结局有1项达到统计学显著差异。
- 最常见不良事件为严重低血糖(CGM组3例、BGM组2例)、高血糖/酮症(CGM组1例、BGM组4例)和糖尿病酮症酸中毒(CGM组3例、BGM组1例)。
- 作者结论认为CGM较标准血糖监测小幅但统计学显著改善血糖控制,需进一步研究理解该发现的临床重要性。
适用人群与场景
- 美国14家内分泌诊所纳入的14–24岁1型糖尿病患者,筛查HbA1c 7.5%–10.9%。
处置流程与药物剂量
- CGM组接受持续葡萄糖监测,BGM组使用血糖仪进行常规血糖监测。
研究设计与关键结果
- 随机临床试验,2018年1月至2019年5月在美国14家内分泌诊所开展,纳入153例14–24岁1型糖尿病患者,随机分为CGM组(n=74)和BGM组(n=79)。
- CGM组基线HbA1c 8.9%、26周8.5%;BGM组基线及26周均为8.9%;校正组间差值-0.37%(95%CI -0.66%至-0.08%,P=0.01)。
- CGM组68%的参与者在第6个月每周使用CGM至少5天。
- 20项预设次要终点中,7项二分类HbA1c终点有3项、9项CGM指标有8项、4项患者报告结局有1项达到统计学显著差异。
- 最常见不良事件:严重低血糖CGM组3例、BGM组2例;高血糖/酮症CGM组1例、BGM组4例;糖尿病酮症酸中毒CGM组3例、BGM组1例。
证据类型、等级与局限
- 证据类型:随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在青少年和年轻成人1型糖尿病患者中,持续葡萄糖监测相比标准血糖监测在26周内小幅但统计学显著改善血糖控制;需进一步研究理解该发现的临床重要性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Adolescents and young adults with type 1 diabetes exhibit the worst glycemic control among individuals with type 1 diabetes across the lifespan. Although continuous glucose monitoring (CGM) has been shown to improve glycemic control in adults, its benefit in adolescents and young adults has not been demonstrated.
OBJECTIVE: To determine the effect of CGM on glycemic control in adolescents and young adults with type 1 diabetes.
DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial conducted between January 2018 and May 2019 at 14 endocrinology practices in the US including 153 individuals aged 14 to 24 years with type 1 diabetes and screening hemoglobin A1c (HbA1c) of 7.5% to 10.9%.
INTERVENTIONS: Participants were randomized 1:1 to undergo CGM (CGM group; n = 74) or usual care using a blood glucose meter for glucose monitoring (blood glucose monitoring [BGM] group; n = 79).
MAIN OUTCOMES AND MEASURES: The primary outcome was change in HbA1c from baseline to 26 weeks. There were 20 secondary outcomes, including additional HbA1c outcomes, CGM glucose metrics, and patient-reported outcomes with adjustment for multiple comparisons to control for the false discovery rate.
RESULTS: Among the 153 participants (mean [SD] age, 17 [3] years; 76 [50%] were female; mean [SD] diabetes duration, 9 [5] years), 142 (93%) completed the study. In the CGM group, 68% of participants used CGM at least 5 days per week in month 6. Mean HbA1c was 8.9% at baseline and 8.5% at 26 weeks in the CGM group and 8.9% at both baseline and 26 weeks in the BGM group (adjusted between-group difference, -0.37% [95% CI, -0.66% to -0.08%]; P = .01). Of 20 prespecified secondary outcomes, there were statistically significant differences in 3 of 7 binary HbA1c outcomes, 8 of 9 CGM metrics, and 1 of 4 patient-reported outcomes. The most commonly reported adverse events in the CGM and BGM groups were severe hypoglycemia (3 participants with an event in the CGM group and 2 in the BGM group), hyperglycemia/ketosis (1 participant with an event in CGM group and 4 in the BGM group), and diabetic ketoacidosis (3 participants with an event in the CGM group and 1 in the BGM group).
CONCLUSIONS AND RELEVANCE: Among adolescents and young adults with type 1 diabetes, continuous glucose monitoring compared with standard blood glucose monitoring resulted in a small but statistically significant improvement in glycemic control over 26 weeks. Further research is needed to understand the clinical importance of the findings.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03263494.
参考来源
- Laffel LM, Kanapka LG, Beck RW, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2020. PMID: 32543683. doi:10.1001/jama.2020.6940
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。